How Marco Pharma International Preserves German Homeopathic Traditions in America 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
LAWRENCE, Mass., April 16, 2018 -- Boston Therapeutics Inc. (the “Company” or “BTI”) (OTCQB:BTHE), an innovator in the design, development and commercialization of novel therapeutics for the potential treatment of diabetes and related complications, will hold a conference call on Wednesday, April 18, 2018 at 5:00 p.m. Eastern time (2:00 p.m. Pacific time) to discuss recent business developments, including its recent acquisition of CureDM and recently announced intention to acquire Medical Technology Associates II, Inc. Boston Therapeutics management will host the presentation, followed by a question and answer period.
Date: Wednesday, April 18, 2018
Time: 5:00 p.m. Eastern time (2:00 p.m. Pacific time)
U.S. dial-in: 1-800-263-0877
TOLL/INTERNATIONAL dial-in: 1-323-794-2094
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact ViaVid at toll-free (888) 562-0262 | tel (604) 929-1352.
The conference call will be broadcast live and available for replay at the Investor Relations section of Boston Therapeutics website. A replay of the conference call will be available after 8:00 p.m. Eastern time on the same day through May 02, 2018.
Toll-free replay number: 1-844-512-2921
International replay number: 1-412-317-6671
Replay ID: 2971422
Investor Relations Contact: Loraine V. Upham
About Boston Therapeutics, Inc. www.bostonti.com
Boston Therapeutics, headquartered in Lawrence, MA (OTCQB:BTHE) and with an office in Albuquerque, NM is an innovator in design, development and commercialization of novel compounds to treat diabetes and diabetes related complications. The company has proprietary compounds based on glucose chemistry, peptide chemistry and protein conjugates.
Contact: Boston Therapeutics, Inc.
Loraine Upham, COO
Phone: 603-935-9799
Email: [email protected]
www.bostonti.com
